Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Final submission from Genentech focuses on revised indication and Risk Evaluation and Mitigation Strategy to support continued approval while it conducts another confirmatory trial.